Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
Calcineurin inhibitors (CNI e.g. tacrolimus) reduce short-term kidney transplant failure, but chronic nephrotoxicity may contribute to late transplant loss. Elective conversion to inhibitors of the mammalian target of rapamycin pathway (mTOR e.g. sirolimus) might avoid long-term CNI renal damage an...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Wiley
2018
|